Tilray Brands delivered record net revenue in Q2 2026, driven by strong performance in international medical cannabis and pharmaceutical distribution. Despite an improved net loss, profitability remains a challenge. The company moved into a net cash position and reaffirmed its full-year adjusted EBITDA outlook.

Tilray posted net income of $1.5 million in Q1 2026 on revenue of $209.5 million, marking a return to profitability alongside strong performance in cannabis and distribution segments.

Tilray’s Q4 2025 saw a moderate decline in revenue and gross profit compared to the prior year, largely due to impairments and strategic shifts in cannabis and beverage categories. The company still posted positive adjusted net income and continued to grow its distribution and wellness segments.

Tilray Brands faced a steep net loss in Q3 FY2025 driven by a $700M non-cash impairment. However, the company improved gross margins, continued cost-saving initiatives, and expanded its hemp-derived THC beverage distribution.

Tilray Brands reported strong Q2 2025 financial results, with a 29% increase in gross profit year-over-year, reaching $61 million. The company achieved a record Q2 net revenue of $211 million, a 9% increase year-over-year (10% in constant currency).

Tilray Brands reported a 13% year-over-year revenue growth, reaching a record $200 million in net revenue for Q1 2025. The company's gross margin increased by over 500 basis points, representing a 20% year-over-year growth. Tilray Beverages experienced a 132% net revenue growth, and German medical cannabis flower revenue increased by 50% following legalization.

Tilray Brands reported a 26% increase in net revenue for fiscal year 2024, driven by growth across its cannabis, beverage, and wellness businesses. The company achieved record-breaking performance in gross profit and adjusted EBITDA, generated positive adjusted free cash flow, and reduced net convertible debt by approximately $300 million.

Tilray Brands reported a net revenue of $188 million for Q3 fiscal year 2024, representing a 30% increase over the prior year quarter. The company saw significant growth in beverage-alcohol net revenue and global cannabis net revenue. They are guiding to an Adjusted EBITDA target of $60 million to $63 million.

Tilray Brands reported a record Q2 fiscal year 2024 net revenue of $194 million, a 34% increase over the prior year period. The company is reiterating its adjusted EBITDA target of $68 million to $78 million for fiscal year 2024 and continues to expect to generate positive adjusted free cash flow.

Tilray Brands reported a record Q1 net revenue of $177 million, a 15% increase year-over-year. The company also increased its #1 cannabis market share position in Canada to 13.4%. With the acquisition of eight craft beer and beverage brands, Tilray became the 5th largest U.S. craft beer brewer with 5% market share.

Tilray Brands reported a record Q4 with net revenue of $184 million, a 20% increase year-over-year. The company's FY2023 net revenue reached $627 million, with $8 million in net cash from operating activities. Tilray also increased its cannabis market share in Canada to 13% through the HEXO acquisition.

Tilray Brands reported its Q3 fiscal year 2023 financial results, achieving $145.6 million in net revenue and maintaining its #1 cannabis market share in Canada. The company also announced the acquisition of HEXO Corp.

Tilray Brands reported net revenue of $144.1 million and took decisive actions to manage operating cash flow and focus on accretive acquisitions and profitability.

Tilray Brands reported net revenue of $153.2 million for the first quarter of fiscal year 2023. The company maintained its #1 position in Canada with 8.5% cannabis market share and leads in medical cannabis within Germany. Tilray also realized $108 million in annualized cash cost-savings and expects to remove $130 million of costs from the business.

Tilray Brands reported an 8% increase in net revenue for the fourth quarter, reaching $153.3 million. The company faced a net loss of $457.8 million, which included a non-cash impairment of $395.0 million. Adjusted EBITDA remained positive for the 13th consecutive quarter at $11.5 million. The company is on track to deliver $100 million in cost synergies by the end of fiscal year 2023 and expects to be free cash flow positive in its operating business units in fiscal year 2023.

Tilray Brands, Inc. reported financial results for the third fiscal quarter ended February 28, 2022. The company achieved a profitable quarter with a net income of $52.5 million and adjusted EBITDA of $10.1 million. Net revenue increased by 23% to $152 million, and gross profit increased by 31% to $39.8 million compared to the prior year quarter.

Tilray's Q2 2022 financial results showed a ~20% increase in net revenue to $155 million and a net income of $6 million, a $95 million improvement from the prior year quarter. The company also achieved $13.8 million in adjusted EBITDA, marking the 11th consecutive quarter of positive adjusted EBITDA.

Tilray, Inc. reported financial results for the first fiscal quarter ended August 31, 2021. The company achieved a 43% increase in net revenue, reaching $168 million, and a 46% increase in gross profit. Tilray also reported its tenth consecutive quarter of positive adjusted EBITDA.

Tilray reported a 25% increase in net revenue to $142.2 million for the fourth quarter of fiscal year 2021, driven by a 36% increase in cannabis revenue and contributions from beverage alcohol and wellness segments. The company achieved a net income of $33.6 million, a significant improvement from the prior year's net loss, and adjusted EBITDA increased by 285% to $12.3 million. Tilray also reported positive free cash flow of $3.3 million and has achieved $35 million in synergies from the business combination with Aphria.